Evidence map›Paper›PMID 42381118›Full record

ArticleJournal of medicinal chemistry2026

Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids.

Maria Łęcka, Oliwia Gorzeń, Natalia Ćwilichowska-Puślecka, Julia Nguyen, Martyna Majchrzak, Vanessa Pippa, Piotr Jakimowicz, Jerzy Wiśniewski, Bartosz Dołęga-Kozierowski, Piotr Kasprzak and 4 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maria ŁęckaFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Oliwia GorzeńFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Natalia Ćwilichowska-PuśleckaFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Julia NguyenFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Martyna MajchrzakFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Vanessa PippaFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Piotr JakimowiczFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.ORCID 0000-0002-0919-2825
Jerzy WiśniewskiFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Bartosz Dołęga-KozierowskiLower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.
Piotr KasprzakLower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.
Boris TurkJozef Stefan Institute, 1000 Ljubljana,Slovenia.ORCID 0000-0002-9007-5764
Marcin DrągFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.
Rafał MatkowskiLower Silesian Oncology, Pulmonology and Hematology Center, 53-413 Wroclaw, Poland.
Marcin PorębaFaculty of Chemistry, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland.ORCID 0000-0002-0214-6252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cysteine cathepsins, particularly cathepsin S, regulate proteolytic signaling in cancer progression and immune modulation, yet selective tools for individual cathepsins remain limited. Here, we report the design of cathepsin S-selective probes and cathepsin S-cleavable antibody-drug conjugates (ADCs) using substrate profiling with unnatural amino acids. Hybrid Combinatorial Substrate Library (HyCoSuL) screening identified selective tetrapeptide motifs that were used to develop optimized fluorogenic substrates, irreversible inhibitors, and fluorescent activity-based probes with high selectivity for cathepsin S in biochemical and cellular assays. These peptide motifs were then incorporated as cleavable linkers in MMAE-based ADCs targeting HER-2 or TROP-2, enabling cathepsin S-dependent cytotoxicity across breast cancer models with distinct target-expression profiles. Finally, anti-cathepsin S antibodies combined with CyTOF analysis revealed the spatial distribution of cathepsin S and its coexpression with HER-2 and TROP-2 in breast cancer patient samples, suggesting that cathepsin S profiling may help inform future patient stratification strategies for cathepsin S-activated ADC therapy.

Indexed as

Amino AcidsAntineoplastic AgentsCathepsinsImmunoconjugatesBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansProtein EngineeringSubstrate SpecificityAmino AcidsAntineoplastic Agentscathepsin SCathepsinsErb-b2 Receptor Tyrosine KinasesImmunoconjugates

Identifiers

PMID42381118
PMCPMC13403234

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.